Tislelizumab,Sorafenib
BeiGene,bayer
['tislelizumab', 'beigene']
beigene announces data presentations at esmo 2022 including late-breaking oral presentation for tislelizumab in first-line unresectable hepatocellular cancer 
Breaking news from Business Wire